Therefore, the panel felt that the diagnosis was LC sarcoma with aberrant expression of CD163, fitting with the current view of the histogenesis of “composite histiocytoses” from a histiocytic cell pool bearing the BRAFV600E or equivalent mutations and retaining some plasticity [28, 61, 62]. Here, CD163 is linked to sarcoma.